Objective: Long-acting darbepoetin-α (DA) has recently been used to treat renal anemia in patients with chronic renal failure. It is considered clinically useful because its duration of action is longer than that of ...Objective: Long-acting darbepoetin-α (DA) has recently been used to treat renal anemia in patients with chronic renal failure. It is considered clinically useful because its duration of action is longer than that of conventional epoetin-α. In this study, we investigated changes in the levels of the oxidative stress marker malondialdehyde-modified low density lipoprotein (MDA-LDL), renal anemia, and renal function when patients were treated for chronic renal failure switched from epoetin-α to DA. Materials and Methods: The subjects included nine patients with chronic renal failure and renal anemia who were treated with epoetin-α on an outpatient basis at our department. Blood was sampled prior to the switch and at 3, 6, and 12 months after the switch. We then investigated changes in MDA-LDL, hemoglobin (Hb), and creatinine (Cr) levels. Results: There were no significant changes in MDA-LDL and Hb levels after switching to DA. A significant increase was observed in Cr levels after 12 months compared with those prior to switching. Conclusion: Once-a-month administration of DA did not result in an increase in oxidative stress, and therefore, DA is considered capable of controlling renal anemia.展开更多
The antioxidant ability of capsules containing oats avenanthramides on human body was evaluated in present study.Healthy people were randomized to supplementation with oats-derived avenanthramides capsules or placebo ...The antioxidant ability of capsules containing oats avenanthramides on human body was evaluated in present study.Healthy people were randomized to supplementation with oats-derived avenanthramides capsules or placebo for 1 mon.Plasma lipid peroxides and antioxidant status were measured.For 8 capsules （containing 3.12 mg avenanthramides） groups,the levels of serum superoxide dismutase （SOD） and reduced glutathione hormone （GSH） were significantly increased by 8.4 and 17.9%,respectively （P0.05）,and malondialdehyde （MDA） level significantly decreased by 28.1%.The total cholesterol （TC）,triglyceride （TG）,and low density lipoprotein cholesterol （LDL-C） levels were lowered by 11.1,28.1,and 15.1%,respectively （P0.05）.The high density blood lipoprotein cholesterol （HDL-C） levels in the same treat was increased by 13.2%.Based on our research,it can be concluded that oats extract containing avenanthramides possessed a high antioxidative activity on humans.It indicated that oat avenanthramides could be used to prevent hyperlipemic and angiocardiopathy.展开更多
文摘Objective: Long-acting darbepoetin-α (DA) has recently been used to treat renal anemia in patients with chronic renal failure. It is considered clinically useful because its duration of action is longer than that of conventional epoetin-α. In this study, we investigated changes in the levels of the oxidative stress marker malondialdehyde-modified low density lipoprotein (MDA-LDL), renal anemia, and renal function when patients were treated for chronic renal failure switched from epoetin-α to DA. Materials and Methods: The subjects included nine patients with chronic renal failure and renal anemia who were treated with epoetin-α on an outpatient basis at our department. Blood was sampled prior to the switch and at 3, 6, and 12 months after the switch. We then investigated changes in MDA-LDL, hemoglobin (Hb), and creatinine (Cr) levels. Results: There were no significant changes in MDA-LDL and Hb levels after switching to DA. A significant increase was observed in Cr levels after 12 months compared with those prior to switching. Conclusion: Once-a-month administration of DA did not result in an increase in oxidative stress, and therefore, DA is considered capable of controlling renal anemia.
基金supported by the Talent Fund of Chinese Academy of Agricultural Sciences,Chinathe Technology Transformation Fund,the Ministry of Sciences and Technology,China
文摘The antioxidant ability of capsules containing oats avenanthramides on human body was evaluated in present study.Healthy people were randomized to supplementation with oats-derived avenanthramides capsules or placebo for 1 mon.Plasma lipid peroxides and antioxidant status were measured.For 8 capsules （containing 3.12 mg avenanthramides） groups,the levels of serum superoxide dismutase （SOD） and reduced glutathione hormone （GSH） were significantly increased by 8.4 and 17.9%,respectively （P0.05）,and malondialdehyde （MDA） level significantly decreased by 28.1%.The total cholesterol （TC）,triglyceride （TG）,and low density lipoprotein cholesterol （LDL-C） levels were lowered by 11.1,28.1,and 15.1%,respectively （P0.05）.The high density blood lipoprotein cholesterol （HDL-C） levels in the same treat was increased by 13.2%.Based on our research,it can be concluded that oats extract containing avenanthramides possessed a high antioxidative activity on humans.It indicated that oat avenanthramides could be used to prevent hyperlipemic and angiocardiopathy.
